Health Care 3.0

Health Care Trends With a Social Media Twist

FDA and social media: The regulated community's current obsession overlooks off-label promotions by the advocacy community

FDA and social media: The regulated community's current obsession overlooks off-label promotions by the advocacy community

This morning I received a tweet exhorting me to learn about Low Dose Naltrexone (LDN) for autoimmune diseases. (Naltrexone, by the way, is approved by the FDA only to treat alcoholism.) Within a few clicks, I found claims that LDN would be a good drug to take for dozens of conditions: everything from neuroblastoma to HIV to celiac disease, and learned of a network of tweeps promoting LDN.

The above tweet linked to a blog promoting LDN which is part of the Health Central community.

All this got me thinking about a bunch of issues; ....

Continue reading this post here.

Views: 3

Tags: off-label, pharma, social media

Comment

You need to be a member of Health Care 3.0 to add comments!

Join Health Care 3.0

A community discussing and debating current health care trends, often those involving social media.

Members

© 2013   Created by Palmer Reuther.   Powered by

Badges  |  Report an Issue  |  Terms of Service